Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
2023-507329-40-00Phase 4Authorised
- Sponsor
- AbbVie Inc.
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 4, open-label, single-arm trial of ibrutinib in follicular lymphoma (FL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM) and 8 more, sponsored by AbbVie Inc. Primary endpoint: Percentage of patients rolling over from each parent study. Planned start Aug 2024; status: authorised.
02
Drugs
ibrutinib
03
Conditions
follicular lymphoma (FL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Waldenström macroglobulinemia (WM)multiple myeloma (MM)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on 2023-507329-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507329-40-00.